PRESS RELEASE published on 02/12/2026 at 18:00, 8 months 17 days ago THX Pharma to Host a Webinar to Discuss Its Strategic Agreement with Biocodex THX Pharma to host webinar discussing strategic agreement with Biocodex, including licensing terms and development outlook. Webcast on February 17, 6:00 p.m. CET. More info at theranexus.com Webinar Strategic Agreement Neurological Diseases THX Pharma Biocodex
BRIEF published on 02/10/2026 at 18:05, 8 months 19 days ago Strategic Licensing Agreement for Rare Disease Treatments Rare Diseases Strategic Agreement Licensing Deal THX Pharma Biocodex
BRIEF published on 02/10/2026 at 18:05, 8 months 19 days ago Strategic agreement between THX Pharma and Biocodex for three rare diseases Rare Diseases License Agreement THX Pharma Biocodex Batten-1 And TX01
PRESS RELEASE published on 02/10/2026 at 18:00, 8 months 19 days ago THX Pharma and Biocodex announce a strategic licensing agreement covering three rare diseases Biocodex acquires licenses from THX Pharma to develop Batten-1 globally and TX01 in US and Canada. Deal worth up to €173M includes milestone payments and double-digit royalties Batten-1 Licenses TX01 THX Pharma Biocodex
BRIEF published on 01/27/2026 at 18:05, 9 months 5 days ago Theranexus Liquidity Contract Half-Year Review Liquidity Contract PORTZAMPARC Financial Report Theranexus THX Pharma Actions
BRIEF published on 01/20/2026 at 18:05, 9 months 12 days ago THX Pharma Reveals 2026 Financial Schedule Financial Calendar Neurological Diseases Market Communication 2026 Announcements THX Pharma
BRIEF published on 01/20/2026 at 18:05, 9 months 12 days ago THX Pharma unveils its 2026 financial calendar Euronext Paris Financial Agenda Biopharmaceutical 2026 THX Pharma
PRESS RELEASE published on 01/20/2026 at 18:00, 9 months 12 days ago THX Pharma Announces its 2026 Financial Calendar THX Pharma (Theranexus) announces financial communication agenda for 2026, focusing on rare neurological diseases treatments. Company listed on Euronext Growth Paris Euronext Growth Paris Financial Communication Theranexus Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 9 months 24 days ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 9 months 24 days ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
Published on 10/30/2026 at 23:35, 2 days 5 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 5 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 10 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 13 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 18 hours 52 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 12 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 6 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 6 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 11 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 17 hours ago Capital increase through exercise of subscription rights
